Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.20% | 77.01% | -18.89% | -69.51% | -36.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.20% | 77.01% | -18.89% | -69.51% | -36.01% |
| Cost of Revenue | -30.08% | -31.88% | 882.96% | 886.23% | 3,675.38% |
| Gross Profit | 13.35% | 57.06% | -542.88% | -220.91% | -220.96% |
| SG&A Expenses | 0.81% | -3.20% | -8.25% | -9.52% | -1.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.02% | -24.53% | -38.97% | -45.49% | -22.41% |
| Operating Income | 1.45% | 40.37% | 42.66% | 30.96% | 15.33% |
| Income Before Tax | 3.64% | 41.03% | 45.50% | 40.77% | 20.91% |
| Income Tax Expenses | 208.24% | 145.14% | 1.40% | -13.83% | -2.30% |
| Earnings from Continuing Operations | 1.74% | 39.89% | 45.24% | 40.58% | 20.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.74% | 39.89% | 45.24% | 40.58% | 20.78% |
| EBIT | 1.45% | 40.37% | 42.66% | 30.96% | 15.33% |
| EBITDA | 0.84% | 40.60% | 43.07% | 31.46% | 15.81% |
| EPS Basic | 3.36% | 40.96% | 46.32% | 41.28% | 21.44% |
| Normalized Basic EPS | 0.73% | 51.28% | 46.58% | 41.45% | 21.57% |
| EPS Diluted | 3.36% | 40.96% | 46.32% | 41.28% | 21.44% |
| Normalized Diluted EPS | 0.73% | 51.28% | 46.58% | 41.49% | 21.62% |
| Average Basic Shares Outstanding | 1.21% | 1.60% | 1.97% | 1.87% | 1.86% |
| Average Diluted Shares Outstanding | 1.21% | 1.60% | 1.97% | 1.29% | 1.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |